Related Experiment Video
Updated: Sep 21, 2025
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
9.2K
Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy
Haixiao Wu1,2, Guijun Xu2,3, Zhijun Li1,2
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Aging
|May 31, 2022
Summary
High-dose methotrexate (MTX) for osteosarcoma (OS) can cause leukopenia (LP). Female sex, high Ki-67, MTX levels, AST, and platelet count predict LP risk in OS patients.
Area of Science:
- Oncology
- Pharmacology
- Biostatistics
Background:
- Osteosarcoma (OS) treatment often involves high-dose methotrexate (MTX).
- Leukopenia (LP) is a common side effect of MTX chemotherapy.
- Predicting and managing LP is crucial for optimizing OS treatment outcomes.
Purpose of the Study:
- To analyze plasma drug concentration trends of MTX in osteosarcoma patients.
- To identify risk factors associated with leukopenia following MTX treatment.
- To develop a predictive nomogram for leukopenia in OS patients.
Main Methods:
- Retrospective analysis of 35 osteosarcoma patients receiving MTX (construction cohort) and 12 patients (validation cohort).
- Monitoring of plasma MTX concentrations at multiple time points post-administration.
- Logistic regression analysis to identify risk factors for leukopenia, followed by nomogram construction and validation.
Main Results:
- Analysis included 128 MTX chemotherapy cycles.
- Identified risk factors for post-chemotherapy leukopenia included female sex, Ki-67 index >20%, MTX concentration >112μmol/L at 6h, platelet count, and AST.
- A predictive nomogram for leukopenia was successfully created and validated.
Conclusions:
- Female sex, MTX concentration at 6h, Ki-67 index, AST, and platelet count are significant risk factors for leukopenia in OS patients treated with MTX.
- The developed nomogram provides a tool for personalized prediction of leukopenia, aiding in treatment management for OS patients receiving MTX chemotherapy.
